TCBP

TC BioPharm (Holdings) PLC Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cbiopharm.com
Employees(FY) 60
ISIN US87807D5095

Performance

+13.03%

+10.87%

-89.41%

-93.05%

-97.92%

YTD

-96.81%

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of TCBP 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 36 indicating a bearish outlook, while the Oscillators Score of 53 suggests a neutral stance, and the overall Technical Score of 45 reinforces a cautious sentiment. This combination points to a generally uncertain market environment, where bearish signals dominate b...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TCBP

Stock Rank

Recent News & Updates

2024-12-19 19:30
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients(Prnewswire)
2024-12-17 19:30
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend(Prnewswire)
2024-12-10 18:00
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy(Prnewswire)
2024-12-03 19:30
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial(Prnewswire)
2024-11-11 20:30
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex Grant(Prnewswire)
2024-10-29 20:30
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements(Yahoo Finance)
2024-10-24 21:45
TCBP Responds to False Social Media Claim(Prnewswire)
2024-10-21 20:30
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic(Prnewswire)
2024-10-02 20:30
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening(Prnewswire)
2024-09-24 20:30
TCBP Announces Site Opening of Guys and St. Thomas Hospital(Prnewswire)
2024-09-23 20:45
TCBP to Present at the 2024 ThinkEquity Conference in NYC(Prnewswire)
2024-09-20 04:00
/C O R R E C T I O N -- TC BioPharm/(Yahoo Finance)
2024-09-12 08:30
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial(PR Newswire)
2024-09-11 20:30
TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial(Prnewswire)
2024-09-09 08:30
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox(PR Newswire)
2024-09-08 20:30
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox(Prnewswire)
2024-09-06 16:00
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox(PR Newswire)
2024-09-06 04:00
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox(Prnewswire)
2024-09-05 08:30
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference(PR Newswire)
2024-09-04 20:30
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-09-03 08:30
TCBP Announces Dosing of 5 New Patients in ACHIEVE(PR Newswire)
2024-09-02 20:30
TCBP Announces Dosing of 5 New Patients in ACHIEVE(Prnewswire)
2024-08-28 17:15
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering(PR Newswire)
2024-08-28 13:49
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications(PR Newswire)
2024-08-28 05:15
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering(Prnewswire)
2024-08-28 01:50
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications(Prnewswire)
2024-08-15 01:00
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)(Prnewswire)
2024-08-14 23:30
TC BioPharm Announces Closing of $2.0 Million Public Offering(Prnewswire)
2024-08-13 04:30
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering(Prnewswire)
2024-07-30 20:00
TCBP Announces Plan to Implement ADS Ratio Change(Prnewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.